Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 101–200 of 643
Chen, Y.-W., Chen, K.-H., Huang, P.-I., Chen, Y.-C., Chiou, G.-Y., Lo, W.-L., Tseng, L.-M., Hsu, H.-S., Chang, K.-W., & Chiou, S.-H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0504 · Cited by 136
Yue, P., Zhang, X., Paladino, D., Sengupta, B., Ahmad, S., Holloway, R. W., Ingersoll, S. B., & Turkson, J. (2012) · Oncogene · doi:10.1038/onc.2011.409 · Cited by 135
Self-citationA. Tsareva, S., Moriggl, R., Corvinus, F. M., Wiederanders, B., Schutz, A., Kovacic, B., & Friedrich, K. (2007) · Neoplasia · doi:10.1593/neo.06820 · Cited by 136
“gression (cyclin D1, c-myc) and/or preventing apoptosis (bcl-x, mcl-1, survivin) [4,9,10].”
Tan, S. M.-L., Li, F., Rajendran, P., Kumar, A. P., Hui, K. M., & Sethi, G. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.165498 · Cited by 137
“Mcl-1 is highly expressed in tumor cells (Epling-Burnette et al., 2001), and Niu et al.”
BackgroundPiret, J.-P., Minet, E., Cosse, J.-P., Ninane, N., Debacq, C., Raes, M., & Michiels, C. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411858200 · Cited by 134
Amin, H. M., Medeiros, L. J., Ma, Y., Feretzaki, M., Das, P., Leventaki, V., Rassidakis, G. Z., O’Connor, S. L., McDonnell, T. J., & Lai, R. L. (2003) · Oncogene · doi:10.1038/sj.onc.1206849 · Cited by 143
“…& 2003 Nature Publishing Group All rights reserved 0950-9232/03 $25.00 www.nature.com/onc bax, bcl-2, mcl-1, p21waf1, and p27kip1 (Naka et al., 1998; Coqueret and Gascan, 2000; Grad et al., 2000; Alas and Bonavida, 2001; Bowman et al., 2001; Epling-Burnette et al., 2001a; Ning et al., 2001).”
BackgroundInfluentialAhn, K. S., Sethi, G., Sung, B., Goel, A., Ralhan, R., & Aggarwal, B. B. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6696 · Cited by 138
“Suppression of the expression of Bcl-xL and Mcl-1 proved to be useful in cancer therapy by inducing cell apoptosis.”
BackgroundInfluentialFofaria, N. M., & Srivastava, S. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu233 · Cited by 132
“Tyrosine (Y705), which is one of the contingent sites of phosphorylation, enhances the expression of various proliferation and survival genes such as Mcl-1, survivin, Bcl-2 and cyclin D1 (14,22,23).”
BackgroundRetractedNagel‐Wolfrum, K., Buerger, C., Wittig, I., Butz, K., Hoppe‐Seyler, F., & Groner, B. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.170.2.3 · Cited by 149
“21, 22) and the up-regulation of antiapoptotic proteins Bcl-xL and Mcl-1 (16, 23).”
BackgroundBurdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.3925 · Cited by 131
“They include Bcl-xL (5), Mcl-1 (6), cyclin D1 (7), and c-Myc (8).”
Rajendran, P., Li, F., Manu, K. A., Shanmugam, M. K., Loo, S. Y., Kumar, A. P., & Sethi, G. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01187.x · Cited by 131
“highly expressed in tumour cells (Epling-Burnette et al., 2001), and Niu et al.”
BackgroundZhou, J., Ong, C. N., Hur, G. M., & Shen, H. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.014 · Cited by 133
STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications
Kim, J., Patel, M. A., Ruzevick, J., Jackson, C. M., & Lim, M. K. (2014) · Cancers · doi:10.3390/cancers6010376 · Cited by 136
“STAT3 activity is associated with upregulation of anti-apoptotic molecules such as Bcl-XL, Mcl-1, and survivin [52,74–76].”
BackgroundSerine 64 Phosphorylation Enhances the Antiapoptotic Function of Mcl-1
Kobayashi, S., Lee, S.-H., Meng, X. W., Mott, J. L., Bronk, S. F., Werneburg, N. W., Craig, R. W., Kaufmann, S. H., & Gores, G. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610010200 · Cited by 117
Huang, M., Dorsey, J. F., Epling‐Burnette, P. K., Nimmanapalli, R., Landowski, T. H., Mora, L. B., Niu, G., Sinibaldi, D., Bai, F., Kraker, A. J., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1206028 · Cited by 149
“Proteins were detected by enhanced chemiluminescence (ECL) using rabbit anti-mouse secondary antibodies as previously described (Epling-Burnette et al., 2001a).”
BackgroundMethodSelf-citationZhang, T., Li, Y., Park, K. A., Byun, H. S., Won, M., Jeon, J., Lee, Y., Seok, J. H., Choi, S. W., Lee, S. S., et al. (2012) · Autophagy · doi:10.4161/auto.18867 · Cited by 128
“The participation of STAT3 in cell death has been generally understood to be associated with apoptosis, which is consistent with the fact that blocking STAT3 signaling pathway by dominant negative STAT3 mutant or antisense STAT3 leads to apoptosis through suppressing the expression of its target genes, such as Bcl-XL,…”
BackgroundSelf-citationTan, M., Lan, K., Yao, J., Lu, C., Sun, M., Neal, C. L., Lü, J., & Yu, D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2747 · Cited by 132
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas
Kelaïdi, C., Rollot, F., Park, S., Tulliez, M., Christoforov, B., Calmus, Y., Podevin, P., Bouscary, D., Sogni, P., Blanche, P., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403443 · Cited by 125
Haghikia, A., Stapel, B., Ricke‐Hoch, M., & Hilfiker‐Kleiner, D. (2010) · Heart Failure Reviews · doi:10.1007/s10741-010-9170-x · Cited by 121
Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 122
“STAT3 has also been shown to inhibit apoptosis via upregulation of Bcl-xL (Thiel and Treurniet, 1976), Myeloid Cell Leukemia 1 (Mcl-1) (Epling-Burnette et al., 2001), and survivin (Aoki et al.”
BackgroundCell-to-cell adhesion modulates Stat3 activity in normal and breast carcinoma cells
Vultur, A., Cao, J., Arulanandam, R., Turkson, J., Jove, R., Greer, P. A., Craig, A. W., Elliott, B. E., & Raptis, L. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207378 · Cited by 127
“…results have shown that Stat3 signalling contributes to the induction of the antiapoptotic bclxL and mcl-1 genes, thus protecting tumor cells from apoptosis (Bromberg et al., 1999; Catlett-Falcone et al., 1999b; Grandis et al., 2000; Bowman et al., 2001; Epling-Burnette et al., 2001).”
BackgroundSelf-citationSignal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis
Kim, D. J., Chan, K. S., Sano, S., & DiGiovanni, J. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20342 · Cited by 113
Kunnumakkara, A. B., Nair, S. A., Sung, B., Pandey, M. K., & Aggarwal, B. B. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0154 · Cited by 118
“AKBA Down-Regulates the Expression of Antiapoptotic Gene Products STAT3 has been shown to regulate the expression of various gene products involved in proliferation and cell survival (33, 34); thus, whether down-regulation of STAT3 activation by AKBA leads to down-regulation of these gene products was examined.”
BackgroundRetractedHepatocellular carcinoma: signaling pathways, targeted therapy, and immunotherapy
Luo, X., He, X., Zhang, X., Zhao, X., Zhang, Y., Shi, Y., & Hua, S. (2024) · MedComm · doi:10.1002/mco2.474 · Cited by 135
Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice
Zhang, X., Zhang, J., Wang, L., Wei, H., & Tian, Z. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-149 · Cited by 113
“The constantly activated STAT3 contributes to oncogenesis by up-regulation of genes encoding bcl-xl, bcl-2, c-myc, cyclin D1, survivin, mcl-1 [7,8,16,19], and VEGF, IL-10, TGF-β et al [20-22], which can protect apoptosis, enhance cell proliferation, promote angiogenesis and evade immune surveillance [1].”
BackgroundMow, B. M. F., Chandra, J., Svingen, P. A., Hallgren, C. G., Weisberg, E., Kottke, T. J., Narayanan, V. L., Litzow, M. R., Griffin, J. D., Sausville, E. A., et al. (2002) · Blood · doi:10.1182/blood.v99.2.664 · Cited by 119
Loughran, T. P., Zickl, L., Olson, T. L., Wang, V., Zhang, D., Rajala, H. L. M., Hasanali, Z. S., Bennett, J. M., Lazarus, H. M., Litzow, M. R., et al. (2014) · Leukemia · doi:10.1038/leu.2014.298 · Cited by 127
“We previously showed high serum levels of soluble Fas, FASL, interferon-γ, interferon-α2, interleukin-6, interleukin-8 and interleukin-18 in patients with LGL leukemia.16 A fundamental pathogenic mechanism in LGL leukemia is resistance to Fas-mediated death despite high expression of both Fas and FASL in leukemic LGL.…”
InfluentialSelf-citationT Cell and NK Cell Lymphoproliferative Disorders
Greer, J. P., Kinney, M. C., & Loughran, T. P. (2001) · Hematology · doi:10.1182/asheducation-2001.1.259 · Cited by 121
Self-citationHsu, H., Huang, P., Chang, Y., Tzao, C., Chen, Y., Shih, H., Hung, S., Chen, Y., Tseng, L., & Chiou, S. (2011) · Cancer · doi:10.1002/cncr.25869 · Cited by 112
Włodarski, M. W., O’Keefe, C. L., Howe, E. C., Risitano, A. M., Rodriguez, A., Warshawsky, I., Loughran, T. P., & Maciejewski, J. P. (2005) · Blood · doi:10.1182/blood-2004-10-4045 · Cited by 118
Self-citationShah, M. V., Zhang, R., Irby, R., Kothapalli, R., Liu, X., Arrington, T., Frank, B. C., Lee, N. H., & Loughran, T. P. (2008) · Blood · doi:10.1182/blood-2007-11-121871 · Cited by 109
Self-citationDalwadi, H., Krysan, K., Heuze-Vourc'h, N., Dohadwala, M., Elashoff, D., Sharma, S., Cacalano, N., Lichtenstein, A., & Dubinett, S. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1205 · Cited by 107
Nam, S., Williams, A. H., Vultur, A., List, A. F., Bhalla, K. N., Smith, D. D., Lee, F. Y., & Jove, R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0446 · Cited by 116
Self-citationTargeting STAT3 in cancer and autoimmune diseases
Gharibi, T., Babaloo, Z., Hosseini, A., Abdollahpour‐Alitappeh, M., Hashemi, V., Marofi, F., Nejati‐Koshki, K., & Baradaran, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173107 · Cited by 108
Prognostic significance of nuclear pSTAT3 in oral cancer
Macha, M. A., Matta, A., Kaur, J., Chauhan, S. S., Thakar, A., Shukla, N. K., Gupta, S. D., & Ralhan, R. (2011) · Head & Neck · doi:10.1002/hed.21468 · Cited by 104
Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1.
Ma, Y., Cress, W. D., & Haura, E. B. (2003) · PubMed · Cited by 120
Molecular Evidence of Cryptotanshinone for Treatment and Prevention of Human Cancer
Chen, W., Lu, Y., Chen, G., & Huang, S. (2013) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113139990115 · Cited by 104
“It has been speculated that this might be related to inhibition of the transcriptional activity of the signal transducer and activator of transcription 3 (Stat3) [26], as Mcl-1 and survivin are positively regulated by Stat3 at transcriptional level [31, 32].”
BackgroundTeramo, A., Gattazzo, C., Passeri, F., Lico, A., Tasca, G., Cabrelle, A., Martini, V., Frezzato, F., Trimarco, V., Ave, E., et al. (2013) · Blood · doi:10.1182/blood-2012-07-441378 · Cited by 104
“Particularly, it was found that signal transducer and activator of transcription-3 (STAT3) protein, a key component of this signaling, is highly expressed and is constitutively activated in leukemic LGLs compared with peripheral blood mononuclear cells (PBMCs) of healthy individuals.(4,5) STAT3 is a transcription fact…”
BackgroundMethodInfluentialBlockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia
Liu, J. H., Wei, S., Lamy, T., Li, Y., Epling‐Burnette, P. K., Djeu, J. Y., & Loughran, T. P. (2002) · Blood · doi:10.1182/blood.v100.4.1449.h81602001449_1449_1453 · Cited by 102
Self-citationZhang, Y., Du, X., Wang, C., Lin, D., Ruan, X., Feng, Y., Huo, Y., Peng, H., Cui, J., Zhang, T., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.11.023 · Cited by 109
Fitzgerald, J. S., Tsareva, S. A., Poehlmann, T. G., Berod, L., Meißner, A., Corvinus, F. M., Wiederanders, B., Pfitzner, E., Markert, U. R., & Friedrich, K. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.02.025 · Cited by 119
Targeted therapy in T-cell malignancies: dysregulation of the cellular signaling pathways
Zhao, W.-L. (2009) · Leukemia · doi:10.1038/leu.2009.223 · Cited by 105
Khoury, J. D., Medeiros, L. J., Rassidakis, G. Z., McDonnell, T. J., Abruzzo, L. V., & Lai, R. (2003) · The Journal of Pathology · doi:10.1002/path.1254 · Cited by 99
Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors
Ceccon, M., Mologni, L., Bisson, W., Scapozza, L., & Gambacorti-Passerini, C. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0569 · Cited by 95
Wu, W., Takanashi, M., Borjigin, N., Ohno, S.-I., Fujita, K., Hoshino, S., Osaka, Y., Tsuchida, A., & Kuroda, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.587 · Cited by 97
Chan, R. J., Johnson, S. A., Li, Y., Yöder, M. C., & Feng, G. (2003) · Blood · doi:10.1182/blood-2003-04-1171 · Cited by 106
Self-citationLatest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia
Moignet, A., & Lamy, T. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200689 · Cited by 102
Rajala, H. L. M., Olson, T. L., Clemente, M. J., Lagström, S., Ellonen, P., Lundán, T., Hamm, D. E., Zaman, S. A. U., Martí, J. M. L., Andersson, E. I., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.113142 · Cited by 104
Self-citationWeerasinghe, P., Garcia, G., Zhu, Q., Yuan, P., Feng, L., Mao, L., & Jing, N. (2007) · International Journal of Oncology · doi:10.3892/ijo.31.1.129 · Cited by 95
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells
Shastri, A., Choudhary, G. S., Teixeira, M., Gordon-Mitchell, S., Ramachandra, N., Bernard, L., Bhattacharyya, S., Lopez, R., Pradhan, K., Giricz, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120156 · Cited by 98
“Differentially downregulated genes included known leukemogenic cell genes such as interleukin 1 receptor accessory protein (IL1RAP), Musashi 2 (MSI2) and anti-apoptotic myeloid leukemia cell differentiation (MCL1) transcripts(16, 21-23) (Fig.”
BackgroundSelf-citationStat3 as a Potential Target for Cancer Immunotherapy
Kortylewski, M., & Yu, H. (2007) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211327.76266.65 · Cited by 101
Cytokines and signal transduction
Hideshima, T., Podar, K., Chauhan, D., & Anderson, K. C. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.003 · Cited by 104
Huang, S., & Sinicrope, F. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1004 · Cited by 98
“Phosphorylation of STAT3 on Tyr(705) has been shown to control its dimerization, nuclear translocation, DNA binding, and transcriptional activation of target genes, including Mcl-1 (9, 38).”
BackgroundElliott, B. E., Hung, W., Boag, A. H., & Tuck, A. B. (2002) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y02-010 · Cited by 102
“This study suggests a new signalling pathway in the transcriptional regulation of HGF expression in carcinoma cells, and could thus lead to novel strategies for the design of low molecular weight antagonists (Gambarotta et al. 1996; Epling-Burnette et al. 2001) to inhibit HGF gene expression preferentially in breast c…”
BackgroundMolecular markers and targets for colorectal cancer prevention
Janakiram, N. B., & Rao, C. V. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00742.x · Cited by 94
Yang, J., Epling‐Burnette, P. K., Painter, J. S., Zou, J., Bai, F., Sheng, W., & Loughran, T. P. (2007) · Blood · doi:10.1182/blood-2007-06-093823 · Cited by 96
Self-citationTargeting Stat3 with G-Quartet Oligodeoxynucleotides in Human Cancer Cells
Jing, N., Li, Y., Xu, X., Sha, W., Li, P., Feng, L., & Tweardy, D. J. (2003) · DNA and Cell Biology · doi:10.1089/104454903770946665 · Cited by 91
Self-citationYang, J., Liu, X., Nyland, S. B., Zhang, R., Ryland, L. K., Broeg, K., Baab, K. T., Jarbadan, N. R., Irby, R., & Loughran, T. P. (2009) · Blood · doi:10.1182/blood-2009-06-223719 · Cited by 98
Self-citationc-Myc activation by Theileria parasites promotes survival of infected B-lymphocytes
Dessauge, F., Hilaly, S., Baumgartner, M., Blumen, B., Werling, D., & Langsley, G. (2004) · Oncogene · doi:10.1038/sj.onc.1208314 · Cited by 93
“Interestingly, constitutive activation of STAT3 signalling also confers resistance to apoptosis in myeloma cells (Catlett-Falcone et al., 1999) and its inhibition leads to apoptosis of leukaemic large granular lymphocytes (Epling-Burnette et al., 2001).”
BackgroundWang, J.-M., Lai, M.-Z., & Yang-Yen, H.-F. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.1896-1909.2003 · Cited by 90
“On the other hand, the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
BackgroundSelf-citationHepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats
Hafez, M. M., Al-Harbi, N. O., Alhoshani, A., Alhosaini, K. A., Shrari, S. D. A., Al-Rejaie, S. S., Sayed‐Ahmed, M. M., & Al‐Shabanah, O. A. (2015) · Biological Research · doi:10.1186/s40659-015-0022-y · Cited by 96
“Similarly, another study reported that the activation of STAT3 increases Bcl2 mRNA and protein expression [63].”
Guo, J., Wu, G., Bao, J., Hao, W., Lu, J., & Chen, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088140 · Cited by 92
Dutta, P., Sabri, N., Li, J., & Li, W. X. (2014) · JAK-STAT · doi:10.1080/21623996.2014.999503 · Cited by 108
Apoptosis and the response to anticancer therapy
Mow, B. M. F., Blajeski, A. L., Chandra, J., & Kaufmann, S. H. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00007 · Cited by 96
Yang, H. H., Ma, M. H., Vescio, R. A., & Berenson, J. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.06.001 · Cited by 96
STAT3: A Promising Therapeutic Target in Multiple Myeloma
Chong, P. S. Y., Chng, W.-J., & de Mel, S. (2019) · Cancers · doi:10.3390/cancers11050731 · Cited by 89
“STAT3 binding motifs were found in the promoter region of Bcl-xL [21] and Mcl-1 [49], indicating that STAT3 could regulate their expression as a transcription factor.”
BackgroundSignaling pathways in liver cancer: pathogenesis and targeted therapy
Xue, Y., Ruan, Y., Wang, Y., Xiao, P., & Xu, J. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00184-0 · Cited by 97
Wang, K., Scheel-Toellner, D., Wong, S. H., Craddock, R., Caamano, J., Akbar, A. N., Salmon, M., & Lord, J. M. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.1035 · Cited by 85
“Mcl-1 expression is regulated not by NF- B, but by CREB and STAT transcription factors (48, 49), although another Bcl-2 family protein expressed in neutrophils, A1, is regulated by NF- B (50).”
BackgroundLiu, X., Ryland, L. K., Yang, J., Liao, A., Aliaga, C. A., Watters, R. J., Tan, S., Kaiser, J. M., Shanmugavelandy, S. S., Rogers, A., et al. (2010) · Blood · doi:10.1182/blood-2010-02-271080 · Cited by 88
Self-citationThe dual functional role of MicroRNA‐18a (miR‐18a) in cancer development
Shen, K., Cao, Z., Zhu, R., You, L., & Zhang, T. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0250-9 · Cited by 93
Novel therapeutic approaches for multiple myeloma
Hideshima, T., Richardson, P. G. G., & Anderson, K. C. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00053.x · Cited by 91
Nam, S., Xie, J., Perkins, A., Ma, Y., Yang, F., Wu, J., Wang, Y., Xu, R.-Z., Huang, W., Horne, D. A., et al. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.05.002 · Cited by 85
Self-citationDorritie, K. A., McCubrey, J. A., & Johnson, D. E. (2013) · Leukemia · doi:10.1038/leu.2013.192 · Cited by 98
Nano-immunotherapy: Overcoming tumour immune evasion
Guevara, M. L., Persano, F., & Persano, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.010 · Cited by 88
Yoon, J., Werneburg, N. W., Higuchi, H., Canbay, A. E., Kaufmann, S. H., Akgul, C., Edwards, S. W., & Gores, G. J. (2002) · PubMed · Cited by 83
Su, Y., Li, G., Zhang, X., Gu, J., Zhang, C., Tian, Z., & Zhang, J. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.8.6263 · Cited by 82
The pathogenesis and treatment of large granular lymphocyte leukemia
Steinway, S. N., LeBlanc, F., & Loughran, T. P. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.02.001 · Cited by 89
“Constitutive activation of Stat3 has been demonstrated as a unifying feature in LGL leukemia, promoting LGL survival through regulation of anti-apoptotic proteins [39].”
BackgroundSelf-citationVitamin D in hematological disorders and malignancies
Larkin, P. M. K., Olson, K. C., Olson, T. L., Feith, D. J., & Loughran, T. P. (2016) · European Journal Of Haematology · doi:10.1111/ejh.12818 · Cited by 91
Self-citationAntiproliferative Effect of Indole Phytoalexins
Chripková, M., Zigo, F., & Mojžíš, J. (2016) · Molecules · doi:10.3390/molecules21121626 · Cited by 85
STAT3 mutation impacts biological and clinical features of T-LGL leukemia
Teramo, A., Barilà, G., Calabretto, G., Ercolin, C., Lamy, T., Moignet, A., Roussel, M., Pastoret, C., Leoncin, M., Gattazzo, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18711 · Cited by 82
“Epling–Burnette et al [8] first demonstrated constitutive STAT3 activation with Mcl1 upregulation in T-LGL leukemia.”
BackgroundKim, J.-K., Kim, J.-Y., Kim, H.-J., Park, K., Harris, R. A., Cho, W., Lee, J.-T., & Lee, I. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080391 · Cited by 88
“Thus, inhibition of constitutive STAT3 activity by synthetic direct inhibitors or the JAK2 inhibitor AG490 has been shown to induce apoptosis of cancer cells [13,14,21,41-44 , 48 ].”
Schade, A. E., Powers, J. J., Włodarski, M. W., & Maciejewski, J. P. (2006) · Blood · doi:10.1182/blood-2005-08-3076 · Cited by 86
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci200215617 · Cited by 80
Sun, X., Zhang, J., Wang, L., & Tian, Z. (2008) · Cancer Letters · doi:10.1016/j.canlet.2007.12.009 · Cited by 80
Li, J., Favata, M., Kelley, J. A., Caulder, E., Thomas, B., Wen, X., Sparks, R. B., Arvanitis, A., Rogers, J. D., Combs, A. P., et al. (2010) · Neoplasia · doi:10.1593/neo.91192 · Cited by 79
Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress
Dong, L., Jiang, C. C., Thorne, R. F., Croft, A. J., Yang, F., Liu, H., de Bock, C. E., Hersey, P., & Zhang, X. D. (2011) · Oncogene · doi:10.1038/onc.2011.87 · Cited by 80
“Although Mcl-1 is regulated by a number of signaling pathways (Epling-Burnette et al. , 2001; Harding et al. , 2002; Iglesias-Serret et al. , 2003; Wang et al. , 2003; Isomoto et al. , 2005; Piret et al. , 2005; Warr and Shore, 2008), upregulation of Mcl-1 by the UPR appears to be characteristic of…”
InfluentialREG I protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells
Sekikawa, A. M., Fukui, H., Fujii, S., Ichikawa, K., Tomita, S., Imura, J., Chiba, T., & Fujimori, T. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm250 · Cited by 83
Cryptotanshinone, a Stat3 inhibitor, suppresses colorectal cancer proliferation and growth in vitro
Li, W., Saud, S. M., Young, M. R., Colburn, N. H., & Hua, B. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2424-0 · Cited by 85
“Stat3 signaling is involved in cancer progression by upregulating genes promoting cell cycle progression (cyclin D1 and c-myc) and/or preventing apoptosis (Bcl-xL, Bcl-2, and Survivin) [20, 49–51].”
BackgroundCrosstalk of Sp1 and Stat3 signaling in pancreatic cancer pathogenesis
Huang, C., & Xie, K. (2012) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2012.01.003 · Cited by 83
Masciocchi, D., Gelain, A., Villa, S., Meneghetti, F., & Barlocco, D. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.22 · Cited by 78
Epling‐Burnette, P. K., Bai, F., Wei, S., Chaurasia, P., Painter, J. S., Olashaw, N., Hamilton, A. D., Sebti, S. M., Djeu, J. Y., & Loughran, T. P. (2004) · Oncogene · doi:10.1038/sj.onc.1208122 · Cited by 79
“…in the assay well) (% annexin-V-FITC positive in the control well) 100)/(100 (% annexin-V-FITC positive in the control well)) Cell lysis and Western immunoblotting Cells were lysed in cell lysis buffer and Western blot analysis was performed as previously described (Epling-Burnette et al., 2001).”
MethodSelf-citationLarge granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment
Zhang, D., & Loughran, T. P. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.652.3798658 · Cited by 78
Self-citationFuke, H., Shiraki, K., Sugimoto, K., Tanaka, J., Beppu, T., Yoneda, K., Yamamoto, N., Ito, K., Masuya, M., & Takei, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.09.049 · Cited by 79
Arabzadeh, A., Mortezazadeh, T., Aryafar, T., Gharepapagh, E., Majdaeen, M., & Farhood, B. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02099-0 · Cited by 82
Growth factor signaling pathways as targets for prevention of epithelial carcinogenesis
Rho, O., Kim, D. J., Kiguchi, K., & DiGiovanni, J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20665 · Cited by 84
“Stat3-mediated regulation of antiapoptotic genes, such as Mcl-1, Bcl-2, Bcl-xL, and survivin, contributes to cell survival [123–126].”
BackgroundCritical role of STAT3 in melanoma metastasis through anoikis resistance
Fofaria, N. M., & Srivastava, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2251 · Cited by 81
“One of the most critical sites of phosphorylation is at Tyrosine 705 (Y705), which enhances the expression of various proliferation and survival genes such as Bcl-2, Mcl-1, Cyclin D1 and survivin[14, 22, 23].”
BackgroundIshida, F., Matsuda, K., Sekiguchi, N., Makishima, H., Taira, C., Momose, K., Nishina, S., Senoo, N., Sakai, H., Ito, T., et al. (2013) · Cancer Science · doi:10.1111/cas.12341 · Cited by 76
Guo, J., Kim, D., Gao, J., Kurtyka, C., Chen, H., Yu, C., Wu, D., Mittal, A., Beg, A. A., Chellappan, S. P., et al. (2013) · Oncogene · doi:10.1038/onc.2012.39 · Cited by 73
RetractedChetoui, N., Sylla, K., Gagnon-Houde, J.-V., Alcaïde‐Loridan, C., Charron, D. J., Al‐Daccak, R., & Aoudjit, F. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0080 · Cited by 80
“described in leukemia cells (52, 53) and in human hepatocytes (54).”
BackgroundActivating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia
Andersson, E. I., Kuusanmäki, H. A., Bortoluzzi, S., Lagström, S., Parsons, A., Rajala, H. L. M., van Adrichem, A. J., Eldfors, S., Olson, T. L., Clemente, M. J., et al. (2015) · Leukemia · doi:10.1038/leu.2015.263 · Cited by 77
Self-citation
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.